Developing new drugs to target and degrade specific proteins in the brain
Official title: Molecular glue degraders for LRRK2
Funded at Lifesensors, INC. · NIH-11007926 · Data updated 2026-11-12
This study is exploring new tiny molecules that can help break down harmful proteins linked to brain diseases, aiming to create better treatments for conditions affecting the nervous system.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lifesensors, INC. NIH-funded |
| Lab location | 1 site (Malvern, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $299,978 |
| NIH project number | 1R43GM156150-01 |
| Project ID | NIH-11007926 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with central nervous system disorders that involve problematic protein accumulation.
✕Less likely to help
Patients with conditions unrelated to protein degradation or those not affected by central nervous system diseases may not benefit from this research.
What this research studies
This research focuses on creating molecular glue degraders that can effectively target and degrade proteins associated with central nervous system diseases. By utilizing the ubiquitin proteasome system, the study aims to enhance the degradation of hard-to-target proteins, which could lead to innovative treatments for various neurological conditions. The approach involves designing small molecules that can induce interactions between specific proteins and E3 ligases, facilitating their breakdown at low doses. This method has the potential to overcome limitations faced by traditional drug designs.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with CNS diseases by effectively targeting previously undruggable proteins.
How similar studies have gone: Previous studies have shown promise in the field of targeted protein degradation, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Lifesensors, INC.
Malvern, United States Active
Researchers
- Principal investigator: Kadimisetty, Karteek — Lifesensors, INC.
- Study coordinator: Kadimisetty, Karteek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.